Volume 23 - Issue 12 - December 2015
Research in Review
11/15/2016
A 40-year-old East Indian man presented with a chronic, recurrent, erythematous rash limited to the inguinal and axillary areas for the past 3 years
A 40-year-old East Indian man presented with a chronic, recurrent, erythematous rash limited to the inguinal and axillary areas for the past 3 years
A 40-year-old East Indian...
11/15/2016
The Dermatologist
04/06/2016
In this excerpt from the recently published book, Practical Psoriasis Management, the author discusses the use of apremilast for moderate-to-severe psoriasis.
In this excerpt from the recently published book, Practical Psoriasis Management, the author discusses the use of apremilast for moderate-to-severe psoriasis.
In this excerpt from the...
04/06/2016
The Dermatologist
FDA Alerts
01/25/2016
FDA has approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.
FDA has approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.
FDA has approved nivolumab...
01/25/2016
The Dermatologist
News
01/22/2016
The aerosol foam formulation of fixed combination calcipotriene plus betamethasone dipropionate (Cal/BD, Enstilar) is efficacious in patients with psoriasis vulgaris according to new pooled data from 3 randomized controlled studies presented...
The aerosol foam formulation of fixed combination calcipotriene plus betamethasone dipropionate (Cal/BD, Enstilar) is efficacious in patients with psoriasis vulgaris according to new pooled data from 3 randomized controlled studies presented...
The aerosol foam formulation of...
01/22/2016
The Dermatologist
News
01/22/2016
FDA has approved Allergan’s supplemental new drug application to update the label for dalbavancin (Dalvance) for injection. The expanded label will include a single dose administered as a 30-minute intravenous (IV) infusion of dalbavancin for...
FDA has approved Allergan’s supplemental new drug application to update the label for dalbavancin (Dalvance) for injection. The expanded label will include a single dose administered as a 30-minute intravenous (IV) infusion of dalbavancin for...
FDA has approved Allergan’s...
01/22/2016
The Dermatologist
FDA Alerts
01/16/2016
The FDA recently approved secukinumab (Cosentyx) for 2 new indications for the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).
The FDA recently approved secukinumab (Cosentyx) for 2 new indications for the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).
The FDA recently approved...
01/16/2016
The Dermatologist
News
01/08/2016
A recent open label study,1 conducted between July and September 2012, examined microbial communities of patients with psoriasis vulgaris who were characterized prior and post a 3-week selenium-rich water balneotherapy treatment at the...
A recent open label study,1 conducted between July and September 2012, examined microbial communities of patients with psoriasis vulgaris who were characterized prior and post a 3-week selenium-rich water balneotherapy treatment at the...
A recent open label...
01/08/2016
The Dermatologist
News
01/06/2016
L’Oréal Group’s skincare brand, La Roche-Posay, revealed its My UV Patch, a novel stretchable skin sensor designed to monitor UV exposure and help consumers educate themselves about sun protection, at the Consumer Electronics Show today.
L’Oréal Group’s skincare brand, La Roche-Posay, revealed its My UV Patch, a novel stretchable skin sensor designed to monitor UV exposure and help consumers educate themselves about sun protection, at the Consumer Electronics Show today.
L’Oréal Group’s skincare brand,...
01/06/2016
The Dermatologist
The Dermatopathologist
12/22/2015
Christine R. Moussa, MD; Najiyah Kazi, MD; Richard Bernet, MD; Cynthia M. Magro, MD
A 23-year-old man presented with aclassic presentation of generalized eruptive histiocytosis.
A 23-year-old man presented with aclassic presentation of generalized eruptive histiocytosis.
A 23-year-old man presented with...
12/22/2015
The Dermatologist
Therapeutic Review
12/22/2015
Researchers conducted a systematic literature review of 73 published studies to identify factors associated with treatment non-adherence across diseases in rheumatology, gastroenterology and dermatology.
Researchers conducted a systematic literature review of 73 published studies to identify factors associated with treatment non-adherence across diseases in rheumatology, gastroenterology and dermatology.
Researchers conducted a...
12/22/2015
The Dermatologist
Research in Review
12/21/2015
A 13-year-old boy with a history of chronic atopic dermatitis, which had mainly affected the antecubital and popliteal areas, presented with a diffuse papular eruption in the lower abdomen that had persisted for approximately 9 months.
A 13-year-old boy with a history of chronic atopic dermatitis, which had mainly affected the antecubital and popliteal areas, presented with a diffuse papular eruption in the lower abdomen that had persisted for approximately 9 months.
A 13-year-old boy with a...
12/21/2015
The Dermatologist
Therapeutic Review
12/21/2015
In a study published in American Journal of Clinical Dermatology, researchers analyzed the efficacy of adalimumab (Humira, AbbVie Inc.) in patients with psoriasis who previously received systematic therapy.
In a study published in American Journal of Clinical Dermatology, researchers analyzed the efficacy of adalimumab (Humira, AbbVie Inc.) in patients with psoriasis who previously received systematic therapy.
In a study published...
12/21/2015
The Dermatologist
Therapeutic Review
12/21/2015
The prevalence of non-alcoholic fatty liver disease (NAFLD) in psoriasis patients was evaluated in a cross-sectional study, recently published in Journal of the European Academy of Dermatology and Venereology.
The prevalence of non-alcoholic fatty liver disease (NAFLD) in psoriasis patients was evaluated in a cross-sectional study, recently published in Journal of the European Academy of Dermatology and Venereology.
The prevalence of non-alcoholic...
12/21/2015
The Dermatologist
News
12/21/2015
Apremilast, an oral phosphodiesterase-4 inhibitor, can reduce the severity of nail and scalp psoriasis.
Apremilast, an oral phosphodiesterase-4 inhibitor, can reduce the severity of nail and scalp psoriasis.
Apremilast, an oral...
12/21/2015
The Dermatologist
Spotlight
12/21/2015
Benjamin Barankin, MD, FRCPC
Dr. Ochoa is an associate professor of dermatology at the Keck School of Medicine University of Southern California.
Dr. Ochoa is an associate professor of dermatology at the Keck School of Medicine University of Southern California.
Dr. Ochoa is an associate...
12/21/2015
The Dermatologist
12/18/2015
A look at the biggest advances of 2015 that impact the field of dermatology and patient care.
A look at the biggest advances of 2015 that impact the field of dermatology and patient care.
A look at the biggest advances...
12/18/2015
The Dermatologist
Derm Dx
12/18/2015
Bryce D. Beutler, BS
A 51-year-old Caucasian man presented with asymptomatic lesions on his breasts of several years’ duration. Cutaneous examination revealed individual and confluent white-yellow dermal papules and plaques involving the areola and nipple...
A 51-year-old Caucasian man presented with asymptomatic lesions on his breasts of several years’ duration. Cutaneous examination revealed individual and confluent white-yellow dermal papules and plaques involving the areola and nipple...
A 51-year-old Caucasian man...
12/18/2015
The Dermatologist
News
12/18/2015
FDA announced two proposed rules preventing the use of sunlamp products (indoor tanning beds) by minors and reducing the risk of using these devices for adults.
FDA announced two proposed rules preventing the use of sunlamp products (indoor tanning beds) by minors and reducing the risk of using these devices for adults.
FDA announced two proposed rules...
12/18/2015
The Dermatologist
12/18/2015
Steven R. Feldman, MD, PhD
In this supplement, we take stock of where we are now with respect to psoriasis treatment
In this supplement, we take stock of where we are now with respect to psoriasis treatment
In this supplement, we take...
12/18/2015
The Dermatologist
NPF Endorsed Features
12/18/2015
Dermira, Inc., a specialty biopharmaceutical company, announced the completion of patient enrollment for the global CIMPASI-1 clinical trial of certolizumab pegol (Cimzia, UCB Inc.) in adult patients with moderate-to-severe chronic plaque...
Dermira, Inc., a specialty biopharmaceutical company, announced the completion of patient enrollment for the global CIMPASI-1 clinical trial of certolizumab pegol (Cimzia, UCB Inc.) in adult patients with moderate-to-severe chronic plaque...
Dermira, Inc., a specialty...
12/18/2015
The Dermatologist
NPF Endorsed Features
12/18/2015
New research finds the incidence of psoriatic arthritis (PsA) among patients with psoriasis is much greater than previously thought.
New research finds the incidence of psoriatic arthritis (PsA) among patients with psoriasis is much greater than previously thought.
New research finds the incidence...
12/18/2015
The Dermatologist
12/18/2015
In this excerpt from the recently published book, Practical Psoriasis Management, the author discusses the use of apremilast for moderate-to-severe psoriasis.
In this excerpt from the recently published book, Practical Psoriasis Management, the author discusses the use of apremilast for moderate-to-severe psoriasis.
In this excerpt from the...
12/18/2015
The Dermatologist
NPF Endorsed Features
12/18/2015
Eileen Koutnik-Fotopoulos
This article reviews the current biologic therapies for the treatment of psoriasis and psoriatic arthritis, discusses the importance of patient and clinician education in the decision-making process and highlights drugs in the...
This article reviews the current biologic therapies for the treatment of psoriasis and psoriatic arthritis, discusses the importance of patient and clinician education in the decision-making process and highlights drugs in the...
This article reviews...
12/18/2015
The Dermatologist
12/16/2015
Posters from the Fall clinical conference look at patient experiences with psoriasis, as well as therapies for this common chronic skin disease.
Posters from the Fall clinical conference look at patient experiences with psoriasis, as well as therapies for this common chronic skin disease.
Posters from the Fall clinical...
12/16/2015
The Dermatologist
12/16/2015
FEATURES
JANUARY – VOLUME 23, ISSUE 1
Business Insider Series: Leveraging Aesthetic Devices in Your Practice
No. 1, p. 22
Exploring Aesthetic Interventions: Fat Transfer for Mid-Face Lipoatrophy
No. 1, p. 30
Clinical Insights on...
FEATURES
JANUARY – VOLUME 23, ISSUE 1
Business Insider Series: Leveraging Aesthetic Devices in Your Practice
No. 1, p. 22
Exploring Aesthetic Interventions: Fat Transfer for Mid-Face Lipoatrophy
No. 1, p. 30
Clinical Insights on...
FEATURES
JANUARY – VOLUME 23,...
12/16/2015
The Dermatologist
Therapeutic Review
12/16/2015
Researchers conducted a retrospective analysis of a group of adolescents (age <17 years) and children with plaque psoriasis treated with cyclosporine at multiple dermatology clinics in Italy. They set out to evaluate the efficacy and...
Researchers conducted a retrospective analysis of a group of adolescents (age <17 years) and children with plaque psoriasis treated with cyclosporine at multiple dermatology clinics in Italy. They set out to evaluate the efficacy and...
Researchers conducted a...
12/16/2015
The Dermatologist
Voices
12/16/2015
Richard G. Fried, MD, PhD
The recent approval of an injectable for submental fat has brought more men into the clinic.
The recent approval of an injectable for submental fat has brought more men into the clinic.
The recent approval of an...
12/16/2015
The Dermatologist
Board Review
12/16/2015
Bruce Theirs, MD, FAAD
1. Immunohistochemical staining shows strong reactivity for the p53 protein. The most likely diagnosis is:
1. Immunohistochemical staining shows strong reactivity for the p53 protein. The most likely diagnosis is:
1. Immunohistochemical...
12/16/2015
The Dermatologist
News
12/16/2015
Nivolumab (Opdivo, Bristol-Myers Squibb Company) injection received FDA approval for intravenous use as a single agent for the treatment of patients with BRAF V600 wild-type (WT) unresectable or metastatic melanoma.
Nivolumab (Opdivo, Bristol-Myers Squibb Company) injection received FDA approval for intravenous use as a single agent for the treatment of patients with BRAF V600 wild-type (WT) unresectable or metastatic melanoma.
Nivolumab (Opdivo, Bristol-Myers...
12/16/2015
The Dermatologist
Chief Medical Editor Message
12/16/2015
Steven R. Feldman, MD, PhD
Humans tolerate (perhaps even pursue) work, as long as that work has meaning. Fortunately for us dermatologists, our work is tremendously meaningful, changing the lives of patients. We are at the frontlines, and can see the benefit of what we...
Humans tolerate (perhaps even pursue) work, as long as that work has meaning. Fortunately for us dermatologists, our work is tremendously meaningful, changing the lives of patients. We are at the frontlines, and can see the benefit of what we...
Humans tolerate (perhaps even...
12/16/2015
The Dermatologist
